Radiotherapy Market Report 2026

The radiotherapy market size has grown strongly in recent years. It will grow from $7.89 billion in 2025 to $8.44 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to expansion of hospital radiotherapy infrastructure, rising global cancer prevalence, adoption of linear accelerator technologies, improvements in diagnostic imaging, increased availability of trained radiation oncologists.

The radiotherapy market size is expected to see strong growth in the next few years. It will grow to $10.93 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing investments in proton therapy facilities, rising focus on personalized radiation dosing, expansion of outpatient radiotherapy centers, growing integration of ai-based planning systems, increasing demand for high-precision cancer therapies. Major trends in the forecast period include increasing adoption of advanced external beam techniques, growing use of image-guided and adaptive radiotherapy, rising demand for proton and particle therapy, expansion of multimodal cancer treatment approaches, enhanced focus on treatment planning accuracy.

The rising prevalence of cancer is expected to fuel the growth of the radiotherapy market in the coming years. Cancer is a condition marked by the uncontrolled growth of abnormal cells that can invade and spread to other parts of the body, originating in different tissues and organs and resulting in varied cancer types and symptoms. The increasing incidence of cancer is driven by factors such as an aging population, lifestyle changes including unhealthy diets and sedentary habits, high consumption of tobacco and alcohol, environmental pollution, and improvements in diagnostic technologies that enable earlier and more frequent detection. Radiotherapy plays a vital role in cancer care by precisely targeting and destroying cancer cells, helping to shrink tumors and improve patient outcomes. For instance, in August 2024, according to Macmillan Cancer Support, a UK-based charitable organization supporting people with cancer, more than 3 million individuals in the UK were living with cancer in 2024, with projections indicating this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the radiotherapy market.

Major companies operating in the radiotherapy market are prioritizing the development of advanced technologies, such as image-guided radiotherapy (IGRT), to enhance treatment accuracy, minimize exposure to healthy tissues, and improve patient outcomes. Image-guided radiotherapy involves the use of sophisticated imaging systems, including onboard CT or MRI, together with adaptive software to track and adjust radiation delivery in real time based on tumor position and movement. For instance, in May 2024, Elekta AB, a Sweden-based medical technology company, introduced the Elekta Evo CT-Linac, a next-generation adaptive radiotherapy system that incorporates high-definition, AI-enhanced imaging and an online adaptive workflow. The system is designed to support clinicians in delivering more precise and personalized radiation therapy across a broad range of treatment protocols while reducing radiation exposure to organs at risk.

In February 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired RayzeBio Inc. for an undisclosed amount. Through this acquisition, Bristol Myers Squibb strengthened its oncology pipeline with advanced radiopharmaceutical therapeutics, including the RYZ101 candidate targeting SSTR2 in GEP-NETs and ES-SCLC. Supported by ongoing clinical trials and a modern manufacturing facility, this acquisition positions the company to accelerate innovation, broaden treatment options, and support growth in the oncology sector. RayzeBio Inc. is a US-based company focused on developing innovative radiopharmaceutical therapies for cancer.

Major companies operating in the radiotherapy market are Hitachi Ltd., GE Healthcare Technologies Inc., Sumitomo Heavy Industries Ltd., Varian Medical Systems Inc., Elekta AB, Accuray Incorporated, Ion Beam Applications S.A, Canon Medical Systems Corporation, RefleXion Medical Inc., Mevion Medical Systems Inc., Nordion Inc., Theragenics Corporation, RaySearch Laboratories AB, MIM Software Inc., Vision RT Ltd., Sun Nuclear Corporation, Provision Healthcare LLC, Panacea Medical Technologies Pvt. Ltd., Optivus Proton Therapy Inc., Perspective Therapeutics Inc., GT Medical Technologies Inc., ProTom International Inc.

North America was the largest region in the radiotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radiotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the radiotherapy market by increasing costs of imported linear accelerators, imaging systems, treatment planning software, and radiation shielding materials. Hospitals and cancer centers in North America and Europe are most affected due to reliance on imported high-end radiotherapy equipment, while Asia-Pacific faces cost pressures on technology upgrades. These tariffs are increasing treatment setup costs and delaying equipment replacement cycles. However, they are also encouraging domestic manufacturing, regional service capabilities, and innovation in cost-optimized radiotherapy solutions.

The radiotherapy market research report is one of a series of new reports that provides radiotherapy market statistics, including radiotherapy industry global market size, regional shares, competitors with a radiotherapy market share, detailed radiotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy industry. This radiotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Radiotherapy is a medical treatment that uses high doses of radiation to eliminate cancer cells and reduce tumor size. It is applied in the management of various cancers, either as a standalone treatment or alongside surgery and chemotherapy.

The primary therapy types in radiotherapy include external beam radiation therapy, internal beam radiation therapy, and systemic radiation therapy. External beam radiation therapy uses high-energy radiation delivered from an external machine to precisely target and destroy cancer cells. It is used to treat multiple conditions, including prostate, breast, lung, head and neck, colorectal, gynecological, cervical, and penile cancers, among others, and is utilized by a range of end users such as hospitals and diagnostic laboratories, cancer treatment and research centers, academic institutions, ambulatory surgery centers, and others.

The radiotherapy market includes revenues earned by entities by providing services such as brachytherapy, palliative radiotherapy, proton therapy, and intraoperative radiotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The radiotherapy market consists of sales of patient positioning systems, surface-guided radiation therapy systems (SGRT), CT and MRI simulation systems, and linear accelerators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.